First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Severance Hospital, Yonsei University Health System, Seoul, South Korea
Study leads
Choong-kun Lee
Principal Investigator
Severance Hospital, Yonsei University Health System